(and breakpoint table, MIC and. by author. ESCMID Online Lecture Library. conventions) ECCMID 2011, Milan

Size: px
Start display at page:

Download "(and breakpoint table, MIC and. by author. ESCMID Online Lecture Library. conventions) ECCMID 2011, Milan"

Transcription

1 EUCAST definitions (and breakpoint table, MIC and zone distribution ib ti website ECCMID 2011, Milan conventions) Derek Brown

2 Clinically susceptible/resistant A microorganism is defined as susceptible by a level of antimicrobial activity associated with a high likelihood of therapeutic success A microorganism is defined as resistant by a level l of antimicrobial i activity it associated with a high likelihood of therapeutic failure.

3 Clinically intermediate A microorganism is defined as intermediate t by a level l of antimicrobial i activity associated with uncertain therapeutic ti effect. It implies that an infection due to the isolate may be appropriately treated t in body sites where the drugs are physically concentrated or when a high dosage of drug can be used (In susceptibility testing it also indicates a buffer zone that should prevent small, uncontrolled, technical variation from causing major discrepancies in interpretation)

4 Clinical breakpoints a microorganism is categorized as susceptible (S), intermediate (I) or resistant (R) by applying the appropriate breakpoint in a defined phenotypic test system MICs are the primary breakpoints Breakpoints in other methods are correlated with MIC breakpoints

5 Breakpoints and cut-off values Clinical breakpoints Non-species-related breakpoints Epidemiological cut-off value (ECOFF)

6 Non-species-related breakpoints Pk/Pd (pharmacokinetic/pharmacodynamic) breakpoints Used in clinical breakpoint development Can be a guide to interpretation in situations where there is no species-specific clinical breakpoint

7 Epidemiological cut-off value (ECOFF) MIC value identifying the upper limit of the wild type population A microorganism is defined as wild type (WT) for a species by the absence of acquired and mutational mechanisms of resistance to the agent.

8 EUCAST wild type and ECOFF Wild type ECOFF

9 EUCAST wild type and ECOFF Wild type ECOFF

10 Epidemiological cut-off values (ECOFFs) Estimated by visual inspection or statistically calculated (Turnidge et al CMI 2006;12:418-25) The ECOFF is not changed by sampling time, source (human, animal, environmental), geographical origin Used in clinical breakpoint development and as a sensitive indicator of resistance development in surveillance studies.

11 Relationship between the clinical breakpoints, non-species-related breakpoints and ECOFFs Non-species-related breakpoints will be same as clinical breakpoints unless they split the wild type or there is no resistance There is no definitive relationship between clinical breakpoints and ECOFFs

12 Clinical breakpoint higher than ECOFF Non-sp-related BP S ECOFF R Non-sp-related BP S breakpoint R breakpoint

13 Clinical breakpoint same as ECOFF Non-sp-related BP S R Non-sp-related BP S/I and R breakpoint ECOFF

14 Clinical breakpoint lower than ECOFF Non-sp-related BP S S breakpoint RNon-sp-related BP ECOFF R breakpoint

15 ECOFF and zone diameters ECOFF Wild type

16 EUCAST breakpoint tables v 1.3

17 EUCAST breakpoint table notes Highlight g indicates change since last version

18 EUCAST breakpoint format S, R > MIC R>4 mg/l 8 mg/l Zone R<24mm 23 mm S 1, R >4 Susceptible I Resistant Susceptible I 4 8 S 1, R Resistant

19 EUCAST intermediate category Intermediate category is not displayed e.g. Ciprofloxacin S 0.5 5mg/L, R>1mg/L, Intermediate inferred >0.5-1 mg/l S 22 mm, R<18 mm, Intermediate inferred mm

20 EUCAST table abbreviations - Susceptibility testing not recommended as the species is a poor target for therapy with the drug (do not test, or do not report, or report as R) IE Insufficient i evidence to set a breakpoint (report MIC values with comment but no categorical interpretation)

21 EUCAST table abbreviations NA Not Applicable (used for screening tests when they are not applicable to particular organisms) IP In preparation (breakpoints will be established)

22 EUCAST breakpoint table links to rationale documents Click on antibiotic for Rationale Document

23 EUCAST breakpoint table links to MIC distributions Click on MIC breakpoint for MIC distributions

24 EUCAST breakpoint table links to zone diameter distributions Click on zone breakpoint for zone diameter distributions

25 EUCAST website (

26 EUCAST MIC and zone diameter distributions website

27 EUCAST MIC and zone distributions Select MIC or zone Select agent or diameter distribution species

28 EUCAST MIC and zone distributions Blue indicates wild type Clinical breakpoints and ECOFF Link to graph

29 EUCAST MIC distributions Do not infer resistance rates May include truncated distributions

30 EUCAST MIC distributions Insufficient data to define ECOFF

31 EUCAST zone diameter distributions

32 EUCAST MIC-zone diameter correlation

33 Summary EUCAST provides clinical breakpoints, non-species-related breakpoints and epidemiological cut-off values (ECOFF) Be aware of formatting conventions and abbreviations in EUCAST breakpoint tables and on EUCAST MIC and zone diameter distributions website

What is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden

What is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden What is new in EUCAST 2016 17 South Africa, May, 2016 Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden What is new in EUCAST 2016/17? New organisms with breakpoints (Addendum 2016)

More information

Mupirocin Rationale for the EUCAST clinical breakpoints, version th July 2010

Mupirocin Rationale for the EUCAST clinical breakpoints, version th July 2010 Mupirocin Rationale for the EUCAST clinical breakpoints, version 1.0 6 th July 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European

More information

Voriconazole Rationale for the EUCAST clinical breakpoints, version March 2010

Voriconazole Rationale for the EUCAST clinical breakpoints, version March 2010 Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European

More information

EUCAST-AFST Available breakpoints 2012

EUCAST-AFST Available breakpoints 2012 EUCAST-AFST Available breakpoints th NSMM meeting Göteborg, Sweden October th EUCAST-AFST documents Reference Methods Yeast E.DEF. () TN- E.DEF. (CMI epub July) E.DEF. () TN- E.DEF. () Breakpoints Compound

More information

Cefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010

Cefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010 Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European

More information

Update zu EUCAST 2012 Cornelia Lass-Flörl

Update zu EUCAST 2012 Cornelia Lass-Flörl Update zu EUCAST 2012 Cornelia Lass-Flörl Frühjahrstagung 2012 Paul-Ehrlich-Gesellschaft Sektion Antimykotische Chemotherapie Bonn, 4./5. Mai 2012 Agenda 1. Breakpoints 2. Rationale documents and technical

More information

Methods for colistin testing What works and what does not? Erika Matuschek, Ph D EUCAST Development Laboratory, EDL

Methods for colistin testing What works and what does not? Erika Matuschek, Ph D EUCAST Development Laboratory, EDL Methods for colistin testing What works and what does not? Erika Matuschek, Ph D EUCAST Development Laboratory, EDL 3 rd joint meeting on AMR in Salmonella and Campylobacter, Copenhagen 7 April 2017 Antimicrobial

More information

Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010

Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010 Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Disclosures Pk/Pd of antifungal drugs Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker Dosing should be such that the level of antmicrobial

More information

EUCAST breakpoints. Paul M. Tulkens. Representative of ISC to EUCAST ( ) Member of the EUCAST steering committee ( )

EUCAST breakpoints. Paul M. Tulkens. Representative of ISC to EUCAST ( ) Member of the EUCAST steering committee ( ) 31 May 2012 ISP - WIV, Brussels, Belgium 1 EUCAST breakpoints 31 May 2012 Paul M. Tulkens Representative of ISC to EUCAST (2006 - ) Member of the EUCAST steering committee (2008-2010) Co-Founder and Past-President

More information

Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013

Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013 Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised

More information

EUCAST Frequently Asked Questions. by author. Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator

EUCAST Frequently Asked Questions. by author. Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator EUCAST Frequently Asked Questions Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator Erika Matuschek EUCAST Development Laboratory, Växjö Sweden Monday 24

More information

The CLSI Approach to Setting Breakpoints

The CLSI Approach to Setting Breakpoints The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic

More information

Expert rules in antimicrobial susceptibility testing: State of the art

Expert rules in antimicrobial susceptibility testing: State of the art Expert rules in antimicrobial susceptibility testing: State of the art ESCMID Postgraduate Education Course Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic Hospital Universitario

More information

Reporting blood culture results to clinicians: MIC, resistance mechanisms, both?

Reporting blood culture results to clinicians: MIC, resistance mechanisms, both? Reporting blood culture results to clinicians: MIC, resistance mechanisms, both? Christian G. Giske, MD, PhD Senior Consultant Physician/Associate Professor Department of Clinical Microbiology Karolinska

More information

Antifungal susceptibility testing: Which method and when?

Antifungal susceptibility testing: Which method and when? Antifungal susceptibility testing: Which method and when? Maiken Cavling Arendrup mad@ssi.dk SSI & Juan Luis Rodriguez Tudela jlrtudela@isciii.es ISCIII Agenda Summary of current standards and selected

More information

Why some tests are no longer recommended

Why some tests are no longer recommended 8 th July 2014 Why some tests are no longer recommended Robin A Howe, Cardiff, UK Antimicrobial use in Primary Care Tests that are no longer recommended Burkholderia cepacia complex testing Stenotrophomonas

More information

SCMID Online Lecture Library. by author. Optimizing antimicrobial therapy in the elderly. Dose Finding - The Past

SCMID Online Lecture Library. by author. Optimizing antimicrobial therapy in the elderly. Dose Finding - The Past Optimizing antimicrobial therapy in the elderly Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Dosing should be such that the level of antmicrobial activity is associated

More information

Veterinary and Agrochemical Research Centre

Veterinary and Agrochemical Research Centre Veterinary and Agrochemical Research Centre Report on susceptibility of Salmonella serotypes in Belgium. P. Butaye Susceptibility of Salmonella strains was assessed by MIC determination using Sensititer

More information

Report on susceptibility of Salmonella serotypes in Belgium Vicky Jasson

Report on susceptibility of Salmonella serotypes in Belgium Vicky Jasson CODA-CERVA Report on susceptibility of Salmonella serotypes in Belgium 2014. Vicky Jasson Veterinary and Agrochemical Research Centre 1 Introduction Salmonella is one of the most important bacterial zoonotic

More information

Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets of β-lactams in critically ill patients at first dose: Can we do it with standard dosing?

Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets of β-lactams in critically ill patients at first dose: Can we do it with standard dosing? Oral session: PK/PD-based optimized broad-spectrum beta-lactam therapy (Sunday 10 April, 11:30) Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets of β-lactams in critically ill patients at first

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author www.eucast.org EXPERT RULES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA Departamento de Microbiología II Universidad

More information

LABORATORY BASED DST FOR BEDAQUILINE AND INTRODUCTION IN COUNTRIES

LABORATORY BASED DST FOR BEDAQUILINE AND INTRODUCTION IN COUNTRIES LABORATORY BASED DST FOR BEDAQUILINE AND INTRODUCTION IN COUNTRIES NDWG Annual meeting 2015, Cape Town, South Africa Rigouts Leen, Institute of Tropical Medicine, Antwerp, Belgium 1 Bedaquiline (BDQ) Sirturo

More information

Disclosures. Efficacy of the drug. Optimizing Dosing Based on PKPD- An overview. Dose Finding - The Past

Disclosures. Efficacy of the drug. Optimizing Dosing Based on PKPD- An overview. Dose Finding - The Past Disclosures Optimizing Dosing Based on PKPD- An overview Johan W. Mouton MD PhD FIDSA FAAM Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker This Patient Needs Antibiotics.

More information

Steven D. Brown* and Maria M. Traczewski. The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, Oregon 97070

Steven D. Brown* and Maria M. Traczewski. The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, Oregon 97070 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2010, p. 2063 2069 Vol. 54, No. 5 0066-4804/10/$12.00 doi:10.1128/aac.01569-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Comparative

More information

Update on CLSI and EUCAST

Update on CLSI and EUCAST Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Factors influencing the results of metronidazole resistance testing Elisabeth Nagy Institute of Clinical Microbiology, University of Szeged, National Anaerobe Reference Laboratory, Szeged, Hungary Postgraduate

More information

Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011

Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review

More information

AMR prediction based on WGS data

AMR prediction based on WGS data AMR prediction based on WGS data Valeria Bortolaia, DVM, PhD Research Group for Genomic Epidemiology National Food Institute Technical University of Denmark This lecture How to use WGS for AMR surveillance?

More information

Case Studies, or Verification Vignettes

Case Studies, or Verification Vignettes Case Studies, or Verification Vignettes 1 Vignette #1 Change from One Automated AST to Another Your lab is changing from one FDA-cleared automated AST to another Is a verification study required? 2 Yes

More information

%T MIC MIC. Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration time-killing-curve 1990.

%T MIC MIC. Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration time-killing-curve 1990. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 159( 55 ) ( 2 15 ) %T MIC MIC 2002 30%T MIC 50%T MIC 1000 mg 3 3 /day Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration

More information

Methods for AST: diffusion or dilution? (pro s en con s)

Methods for AST: diffusion or dilution? (pro s en con s) 7 th EURL-AR workshop 4-5 April 2013 DTU, Kgs. Lyngby, Denmark Methods for AST: diffusion or dilution? (pro s en con s) Kees Veldman Introduction Work as a senior technician at the Central Veterinary Institute

More information

breakpoints, cephalosporins, CLSI, Enterobacteriacae, EUCAST, review Clin Microbiol Infect 2008; 14 (Suppl. 1):

breakpoints, cephalosporins, CLSI, Enterobacteriacae, EUCAST, review Clin Microbiol Infect 2008; 14 (Suppl. 1): REVIEW Breakpoints for intravenously used cephalosporins in Enterobacteriaceae EUCAST and CLSI breakpoints G. Kahlmeter Department of Clinical Microbiology, Central Hospital, Växjö, Sweden ABSTRACT It

More information

Attachment 12 URGENT FIELD SAFETY REMOVAL FSCA3193. ETEST Ceftriaxone TXL32 (Ref , ) FOAM packaging

Attachment 12 URGENT FIELD SAFETY REMOVAL FSCA3193. ETEST Ceftriaxone TXL32 (Ref , ) FOAM packaging 16 January 2017 Attachment 12 URGENT FIELD SAFETY REMOVAL FSCA3193 ETEST Ceftriaxone TXL32 (Ref. 507058, 507018) FOAM packaging Dear This letter is intended for all ETEST Ceftriaxone TXL32 (Ref. 507058,

More information

Spectrum of vancomycin and susceptibility testing

Spectrum of vancomycin and susceptibility testing Spectrum of vancomycin and susceptibility testing Olivier Denis Service de Microbiologie Laboratoire de bactériologie Service de Microbiologie Hôpital Erasme Glycopeptides Vancomycin 1958 < Amycolatopsis

More information

Vancomycin Rationale for the EUCAST clinical breakpoints, version June 2010

Vancomycin Rationale for the EUCAST clinical breakpoints, version June 2010 Vancomycin Rationale for the EUCAST clinical breakpoints, version 2.1 17 June 2010 Introduction The glycopeptides are a class of agents composed of amino acid residues and attached sugars. Glycopeptides

More information

T&T WG. June 2018 San Diego, CA

T&T WG. June 2018 San Diego, CA T&T WG June 2018 San Diego, CA Co-Chairs Jana Swenson Shelley Campeau Secretary Carey-Ann Burnham Members Andrea Ferrell Janet Hindler Melissa Jones Peggy Kohner Dyan Luper Linda Mann Susan Munro Barth

More information

Consultation on the Revision of Carbapenem Breakpoints

Consultation on the Revision of Carbapenem Breakpoints Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints

More information

Estimation of In Vitro Susceptibility Breakpoints for Tigecycline Against Staphylococcus aureus

Estimation of In Vitro Susceptibility Breakpoints for Tigecycline Against Staphylococcus aureus Estimation of In Vitro Susceptibility Breakpoints for Tigecycline Against Staphylococcus aureus Alison K Meagher, PharmD Cognigen Corporation 45 th ICAAC December 17, 2005 Julie Passarell, M.A. Cognigen

More information

URGENT FIELD SAFETY NOTICE FSCA3193. Etest Ceftriaxone TXL32 (Ref , ) SPB Packaging

URGENT FIELD SAFETY NOTICE FSCA3193. Etest Ceftriaxone TXL32 (Ref , ) SPB Packaging 16 January 2017 Attachment 3 URGENT FIELD SAFETY NOTICE FSCA3193 Etest Ceftriaxone TXL32 (Ref. 412302, 412303) SPB Packaging Dear This letter is intended for all ETEST Ceftriaxone TXL32 (Ref. 412302, 412303)

More information

Report on the Japanese Veterinary Antimicrobial Resistance Monitoring System

Report on the Japanese Veterinary Antimicrobial Resistance Monitoring System Report on the Japanese Veterinary Antimicrobial Resistance Monitoring System 2014 2015 National Veterinary Assay Laboratory Ministry of Agriculture, Forestry and Fisheries 2018 Contents Introduction...

More information

Pharmacodynamic indices in targeting therapy of critical infections

Pharmacodynamic indices in targeting therapy of critical infections Pharmacodynamic indices in targeting therapy of critical infections P.M. Tulkens Cellular and Molecular Pharmacology, Catholic University of Louvain, Brussels, Belgium & International Society of Anti-infective

More information

GBS Screening, diagnosis and clinically relevant resistance

GBS Screening, diagnosis and clinically relevant resistance GBS Screening, diagnosis and clinically relevant resistance Pierrette Melin National Reference Centre for GBS Medical Microbiology, University Hospital of Liege 1 Background Evolution of culture methods

More information

ECMM Excellence Centers Quality Audit

ECMM Excellence Centers Quality Audit ECMM Excellence Centers Quality Audit Person in charge: Department: Head of Department: Laboratory is accredited according to ISO 15189 (Medical Laboratories Requirements for quality and competence) Inspected

More information

Rapid susceptibility testing: new phenotypic and non-wgs genotypic approaches

Rapid susceptibility testing: new phenotypic and non-wgs genotypic approaches Rapid susceptibility testing: new phenotypic and non-wgs genotypic approaches BSAC Spring Conference 2018 Next generation Antimicrobial Susceptibility Testing of Bacteria Oskar Ekelund, MD Clinical Microbiology

More information

Expert rules. for Gram-negatives

Expert rules. for Gram-negatives Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University

More information

Report: antimicrobial resistance in commensal E. coli from poultry, pigs, cows and veal calves. 2013

Report: antimicrobial resistance in commensal E. coli from poultry, pigs, cows and veal calves. 2013 Veterinary and Agrochemical Research Centre Report: antimicrobial resistance in commensal E. coli from poultry, pigs, cows and veal calves. 2013 1 Introduction Commensal E. coli are regarded as general

More information

Scottish Microbiology and Virology Network. Carbapenemase producers: screening and the new Scottish AMR Satellite Reference Laboratory Service

Scottish Microbiology and Virology Network. Carbapenemase producers: screening and the new Scottish AMR Satellite Reference Laboratory Service Scottish Microbiology and Virology Network Carbapenemase producers: screening and the new Scottish AMR Satellite Reference Laboratory Service Total number of carbapenemase producing organisms isolated

More information

Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)

Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Streptococcus pneumoniae (SP) Blood Culture Isolates Penicillin intermediate Penicillin Cefotaxime 336

More information

Understanding the Dialysis Event Protocol and Avoiding Common Reporting Mistakes Alicia Shugart, MA

Understanding the Dialysis Event Protocol and Avoiding Common Reporting Mistakes Alicia Shugart, MA Understanding the Dialysis Event Protocol and Avoiding Common Reporting Mistakes Alicia Shugart, MA Public Health Analyst Topics Dialysis Event Protocol Collecting data Reporting a numerator and denominator

More information

EARSS in Ireland, Results of invasive Streptococcus pneumoniae infection (blood/csf) surveillance

EARSS in Ireland, Results of invasive Streptococcus pneumoniae infection (blood/csf) surveillance EARSS in Ireland, 2007 Results of invasive Streptococcus pneumoniae infection (blood/csf) surveillance Antibiotic codes and abbreviations: CTX, Ciprofloxacin ERY, Erythromycin OXA, Oxacillin TCY, Tetracycline

More information

AST issues of polymyxins and their implications for the routine laboratory

AST issues of polymyxins and their implications for the routine laboratory AST issues of polymyxins and their implications for the routine laboratory Christian G. Giske, MD/PhD Chief consultant physician/associate professor Chairman of EUCAST Karolinska Institute and University

More information

Clinical relevance of resistance in Aspergillus. David W. Denning University Hospital of South Manchester [Wythenshawe Hospital]

Clinical relevance of resistance in Aspergillus. David W. Denning University Hospital of South Manchester [Wythenshawe Hospital] Clinical relevance of resistance in Aspergillus David W. Denning University Hospital of South Manchester [Wythenshawe Hospital] The University of Manchester Steps to establishing clinical validity of resistance/susceptibility

More information

CHMP extension of indication variation assessment report

CHMP extension of indication variation assessment report 23 April 2015 EMA/CHMP/245949/2015 adopted Committee for Medicinal Products for Human Use (CHMP) Invented name: Tygacil International non-proprietary name: TIGECYCLINE Procedure No. EMEA/H/C/000644/II/0092

More information

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18

More information

Ampicillin Resistance Mechanisms in Clinical Haemophilus influenzae: What is Happening in Portugal?

Ampicillin Resistance Mechanisms in Clinical Haemophilus influenzae: What is Happening in Portugal? Ampicillin Resistance Mechanisms in Clinical Haemophilus influenzae: What is Happening in Portugal? M. Paula Bajanca-Lavado Haemophilus Reference Laboratory Infectious Disease Department National Institute

More information

In vitro cross-resistance between azoles in Aspergillus fumigatus: a reason for concern in the clinic?

In vitro cross-resistance between azoles in Aspergillus fumigatus: a reason for concern in the clinic? 4 th Congress on Trends in Medical Mycology (TIMM) In vitro cross-resistance between azoles in Aspergillus fumigatus: a reason for concern in the clinic? Emilia Mellado Mycolgy Reference Laboratory Centro

More information

BD Diagnostics Integrated Solutions. Identification and Antimicrobial Susceptibility Testing Diagnostics

BD Diagnostics Integrated Solutions. Identification and Antimicrobial Susceptibility Testing Diagnostics BD Diagnostics Integrated Solutions Identification and Antimicrobial Susceptibility Testing Diagnostics Table of contents The threat of antimicrobial resistant bacteria 4 BD Phoenix TM Emerge 5 Financing

More information

prophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures

prophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures 1 Glycopeptides appropriate uses serious infections due to beta-lactam- resistant gram-positive microorganisms infections due to gram-positive microorganisms in patients with serious allergy to beta-lactam

More information

ResFinder 4.0: towards in silico antibiograms

ResFinder 4.0: towards in silico antibiograms ResFinder 4.0: towards in silico antibiograms Valeria Bortolaia, DVM, PhD Research group for Genomic Epidemiology National Food Institute Technical University of Denmark The path to WGS-based AMR prediction

More information

ACCEPTED. Comparison of disk diffusion and agar dilution methods for erythromycin and

ACCEPTED. Comparison of disk diffusion and agar dilution methods for erythromycin and AAC Accepts, published online ahead of print on January 00 Antimicrob. Agents Chemother. doi:./aac.000-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

Pharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of

Pharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with

More information

Linezolid - Tigecycline

Linezolid - Tigecycline Linezolid - Tigecycline Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology Louvain Drug Research Institute Catholic University of Louvain, Brussels, Belgium With the support of Wallonie-Bruxelles-International

More information

Biosecurity in pigs holdings February 2015, State Food and Veterinary Service, Lithuania

Biosecurity in pigs holdings February 2015, State Food and Veterinary Service, Lithuania Biosecurity in pigs holdings 11-12 February 2015, State Food and Veterinary Service, Lithuania 1 Biosecurity measures Order of the Director of the State Food and Veterinary Service No B1-384 of 11 July

More information

Cefazolin and Enterobacteriaceae: Rationale for Revised Susceptibility Testing Breakpoints

Cefazolin and Enterobacteriaceae: Rationale for Revised Susceptibility Testing Breakpoints INVITED ARTICLE MEDICAL MICROBIOLOGY L. Barth Reller and Melvin P. Weinstein, Section Editors Cefazolin and Enterobacteriaceae: Rationale for Revised Susceptibility Testing Breakpoints John D. Turnidge

More information

A Snapshot of Colistin Use in South-East Europe and Particularly in Greece

A Snapshot of Colistin Use in South-East Europe and Particularly in Greece A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia

More information

Therapeutic drug monitoring of β-lactams

Therapeutic drug monitoring of β-lactams CORATA Belgique Reims 1-2/10/2014 Therapeutic drug monitoring of β-lactams Frédéric Cotton Clinical Chemistry Erasme Hospital Faculty of Pharmacy ULB TDM of β-lactams β-lactams pharmacokinetics pharmacodynamics

More information

Endocardite infectieuse

Endocardite infectieuse Endocardite infectieuse 1. Raccourcir le traitement: jusqu où? 2. Proposer un traitement ambulatoire: à partir de quand? Endocardite infectieuse A B 90 P = 0.014 20 P = 0.0005 % infective endocarditis

More information

Standardisation of testing for Carbapenemase Producing Organisms (CPO) in Scotland

Standardisation of testing for Carbapenemase Producing Organisms (CPO) in Scotland Standardisation of testing for Carbapenemase Producing Organisms (CPO) in Scotland Version 1.0 7 June 2017 Revision Date June 2018 Scottish Microbiology and Virology Network (SMVN) SMVN Standardisation

More information

HIV and FDC aspects of two guidelines. Filip Josephson

HIV and FDC aspects of two guidelines. Filip Josephson HIV and FDC aspects of two guidelines Filip Josephson Status Ongoing process Updated draft guideline for HIV drug development available for public consultation on EMA website since 2013 Presently under

More information

Antimicrobial resistance and molecular epidemiology of Neisseria gonorrhoeae in New Zealand,

Antimicrobial resistance and molecular epidemiology of Neisseria gonorrhoeae in New Zealand, Antimicrobial resistance and molecular epidemiology of Neisseria gonorrhoeae in New Zealand, 2014-15 December 2015 PREPARED FOR: CLIENT REPORT No: PREPARED BY: Ministry of Health FW15061 Helen Heffernan,

More information

FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia

FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia Clinical Infectious Diseases Advance Access published July 9, 2014 MAJOR ARTICLE FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia Nicholas D. Beyda, 1 Julie John, 1 Abdullah

More information

Report: antimicrobial resistance in commensal Enterococcus spp. from poultry, pigs, cows and veal calves

Report: antimicrobial resistance in commensal Enterococcus spp. from poultry, pigs, cows and veal calves Veterinary and Agrochemical Research Centre Report: antimicrobial resistance in commensal Enterococcus spp. from poultry, pigs, cows and veal calves P. Butaye 1 Introduction Enterococci are regarded as

More information

Study of Ciprofloxacin Resistant Escherichia coli (CREC) in Type 2 Diabetic Patients with Symptomatic Urinary Tract Infections

Study of Ciprofloxacin Resistant Escherichia coli (CREC) in Type 2 Diabetic Patients with Symptomatic Urinary Tract Infections Study of Ciprofloxacin Resistant Escherichia coli (CREC) in Type 2 Diabetic Patients with Symptomatic Urinary Tract Infections MSc Abstract: Background: Type 2 diabetes is the most common form of diabetes

More information

Towards clinical Applications of PK-PD in specific situations

Towards clinical Applications of PK-PD in specific situations Towards clinical Applications of PK-PD in specific situations P.M. Tulkens Cellular and Molecular Pharmacology & Center for Clinical Pharmacy, Catholic University of Louvain, Brussels, Belgium with many

More information

Comparision of Antibiotic Susceptibility Testing As Per CLSI and Eucast Guidelines for Gram Negative Bacilli

Comparision of Antibiotic Susceptibility Testing As Per CLSI and Eucast Guidelines for Gram Negative Bacilli IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 7 Ver. X (July. 2016), PP 01-05 www.iosrjournals.org Comparision of Antibiotic Susceptibility

More information

Surveillance of Enterococci in Belgium. M. Ieven, K. Loens, B. Jans and H. Goossens

Surveillance of Enterococci in Belgium. M. Ieven, K. Loens, B. Jans and H. Goossens Surveillance of Enterococci in Belgium M. Ieven, K. Loens, B. Jans and H. Goossens Surveillance of Enterococci in Belgium Overview Introduction and epidemiological surveillance Results of isolates received

More information

Trends in Antibiotic Resistance in Coagulase-Negative Staphylococci, United States,

Trends in Antibiotic Resistance in Coagulase-Negative Staphylococci, United States, Supplementary Information For Trends in Antibiotic Resistance in Coagulase-Negative Staphylococci, United States, 1999 2012 Larissa May, a Eili Y. Klein, b,c# Richard E. Rothman, b Ramanan Laxminarayan

More information

Molecular epidemiology and drug resistance mechanism of Salmonella species especially in S. Typhi strains isolated in Bangladesh

Molecular epidemiology and drug resistance mechanism of Salmonella species especially in S. Typhi strains isolated in Bangladesh Molecular epidemiology and drug resistance mechanism of Salmonella species especially in S. Typhi strains isolated in Bangladesh Dr. Kaisar Ali Talukder Senior Scientist Icddr,b This presentation will

More information

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014.

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014. Annual survey of extended-spectrum -lactamase (ESBL)-producing Enterobacteriaceae, 2013 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research

More information

Clinical Practice Guideline on Central Venous Catheter Care for the Patient with Cancer

Clinical Practice Guideline on Central Venous Catheter Care for the Patient with Cancer Clinical Practice Guideline on Central Venous Catheter Care for the Patient with Cancer COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER

More information

Antifungal Susceptibility of Aspergillus Isolates from the Respiratory Tract of Patients in Canadian Hospitals: Results of the CANWARD 2016 Study.

Antifungal Susceptibility of Aspergillus Isolates from the Respiratory Tract of Patients in Canadian Hospitals: Results of the CANWARD 2016 Study. 1 Antifungal Susceptibility of Aspergillus Isolates from the Respiratory Tract of Patients in Canadian Hospitals: Results of the CANWARD 2016 Study. J. FULLER 1,3, A. BULL 2, S. SHOKOPLES 2, T.C. DINGLE

More information

Methicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods

Methicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods Methicillin-Resistant Staphylococcus aureus (MRSA) Surveillance Report 2008 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services

More information

Determination of MIC & MBC

Determination of MIC & MBC 1 Determination of MIC & MBC Minimum inhibitory concentrations (MICs) are defined as the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight

More information

ANALYSIS OF MYCOPLASMA GENITALIUM STRAINS ISOLATED FROM PREGNANT WOMEN AT AN ACADEMIC HOSPITAL IN PRETORIA, SOUTH AFRICA

ANALYSIS OF MYCOPLASMA GENITALIUM STRAINS ISOLATED FROM PREGNANT WOMEN AT AN ACADEMIC HOSPITAL IN PRETORIA, SOUTH AFRICA ANALYSIS OF MYCOPLASMA GENITALIUM STRAINS ISOLATED FROM PREGNANT WOMEN AT AN ACADEMIC HOSPITAL IN PRETORIA, SOUTH AFRICA Mafunise M 1, Le Roux MC 1, de Villiers BE 1, Ditsele RMM 1,2 1 Department of Microbiological

More information

AMR SURVEILLANCE IN THE REPUBLIC OF BELARUS

AMR SURVEILLANCE IN THE REPUBLIC OF BELARUS MINISTRY OF HEALTH OF THE REPUBLIC OF BELARUS THE REPUBLICAN RESEARCH AND PRACTICAL CENTER FOR EPIDEMIOLOGY AND MICROBIOLOGY AMR SURVEILLANCE IN THE REPUBLIC OF BELARUS Leonid P. Titov Associate Member

More information

Academic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE

Academic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE Academic Perspective in Emerging No, we can t Issues treat of carbapenemase Resistance and ESBL in Gram-ve producers Bacteria based on MIC David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic

More information

Scottish Bacterial Sexually Transmitted Infections Reference Laboratory (SBSTIRL) User Report for the period January - December 2011

Scottish Bacterial Sexually Transmitted Infections Reference Laboratory (SBSTIRL) User Report for the period January - December 2011 Scottish Bacterial Sexually Transmitted Infections Reference Laboratory (SBSTIRL) User Report for the period January - ember 211 Kirstine Eastick PhD FRCPath (Director) SBSTIRL, Microbiology Edinburgh

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fusidic Acid 2% Cream SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2 % cream. Each gram contains 20 mg fusidic acid. Excipient(s) with

More information

Emergence, spread and characteristics of Neisseria

Emergence, spread and characteristics of Neisseria Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden Daniel Golparian, Bengt Hellmark,

More information

OIE MEMBER COUNTRY OBLIGATIONS FOR EMERGING DISEASES

OIE MEMBER COUNTRY OBLIGATIONS FOR EMERGING DISEASES OIE MEMBER COUNTRY OBLIGATIONS FOR EMERGING DISEASES Dr. Jie Huang Aquatic Animal Health Standards Commission The OIE 1/23/15 1 Conception of Emerging Diseases ß ß 2003 (TC): no definition 2005 (TC) ß

More information

Campylobacter at HPA Colindale. Dr Andy Lawson Centre for Infections Health Protection Agency London

Campylobacter at HPA Colindale. Dr Andy Lawson Centre for Infections Health Protection Agency London Campylobacter at HPA Colindale Dr Andy Lawson Centre for Infections Health Protection Agency London Health Protection Agency Establised in 2003, functions as a non-departmental public body. The HPA has

More information

Is the package insert correct? PK considerations

Is the package insert correct? PK considerations Is the package insert correct? PK considerations Jason A Roberts B Pharm (Hons), PhD, FSHP Professor of Medicine and Pharmacy The University of Queensland, Australia Royal Brisbane and Women s Hospital,

More information

Educational Workshops 2016

Educational Workshops 2016 Educational Workshops 2016 Keynote CPE Screening We are grateful to Dr Andrew Dodgson, Consultant Microbiologist, Public Health England and Central Manchester Hospitals NHS Foundation Trust Terminology

More information

Discussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category

Discussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide

More information

Should we be performing TDM in seriously ill patients with Gram negative infections?

Should we be performing TDM in seriously ill patients with Gram negative infections? Should we be performing TDM in seriously ill patients with Gram negative infections? Jason A Roberts B Pharm (Hons), PhD, FSHP Royal Brisbane and Women s Hospital, Australia. The University of Queensland,

More information

Dialysis Event Reporting ESRD Network 8 LAN June 18, 2014

Dialysis Event Reporting ESRD Network 8 LAN June 18, 2014 Dialysis Event Reporting ESRD Network 8 LAN June 18, 2014 Meredith Kanago, MSPH Epidemiologist, Healthcare Associated Infections and Antimicrobial Resistance Program, Tennessee Department of Health Acknowledgements

More information

Summary comments: An essential pattern employed by all living things: DNA ö RNA ö Protein

Summary comments: An essential pattern employed by all living things: DNA ö RNA ö Protein Summary comments: An essential pattern employed by all living things: DNA ö RNA ö Protein DNA is the information storage molecule. RNA in an intermediate in information flow. Proteins do most of the jobs

More information

Received 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011

Received 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011 JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1765 1771 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.02517-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multicenter

More information

PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS

PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS

More information